Janssen Sues Sandoz Over Alzheimer's Drug ANDA

Law360, New York (June 13, 2008, 12:00 AM EDT) -- Three Johnson & Johnson subsidiaries launched a patent infringement suit last week against Novartis AG’s generics arm, Sandoz Inc., after the generics maker filed an abbreviated new drug application for the Alzheimer’s drug Razadyne ER.

The complaint filed in the U.S. District Court for the District of New Jersey alleges Sandoz’s ANDA filing with the U.S. Food and Drug Administration infringes on a patent held by Janssen LLP, a Johnson & Johnson unit.

Sandoz allegedly intends to bring to market a generic version of galantamine hydrobromide...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.